Amylyx Pharmaceuticals (AMLX) Gross Margin (2022 - 2024)
Historic Gross Margin for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q4 2024 value amounting to 100.0%.
- Amylyx Pharmaceuticals' Gross Margin rose 73900.0% to 100.0% in Q4 2024 from the same period last year, while for Sep 2025 it was 100.0%, marking a year-over-year increase of 70700.0%. This contributed to the annual value of 94.79% for FY2024, which is 6900.0% up from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Gross Margin stood at 100.0% for Q4 2024, which was up 73900.0% from 100.0% recorded in Q3 2024.
- In the past 5 years, Amylyx Pharmaceuticals' Gross Margin ranged from a high of 100.0% in Q3 2024 and a low of 68.56% during Q3 2022
- Moreover, its 3-year median value for Gross Margin was 94.3% (2023), whereas its average is 92.7%.
- In the last 5 years, Amylyx Pharmaceuticals' Gross Margin skyrocketed by 267800bps in 2023 and then plummeted by -4600bps in 2024.
- Quarter analysis of 3 years shows Amylyx Pharmaceuticals' Gross Margin stood at 89.38% in 2022, then increased by 4bps to 92.61% in 2023, then increased by 8bps to 100.0% in 2024.
- Its Gross Margin stands at 100.0% for Q4 2024, versus 100.0% for Q3 2024 and 99.22% for Q2 2024.